Insulinoma Clinical Trial
Official title:
Application of Raw Corn Starch on Patients With Unoperated Insulinoma is Helpful to Decrease Risk of Hypoglycemia
This will be a prospective single-arm before-and-after clinical trial in which raw corn starch (RCS) will be first applied on patients with unoperated insulinoma. Nutritional intervention with supplementation of RCS will be initiated in 20 patients with suspected insulinoma to improve their hypoglycemia before the surgery. Duration of nutritional intervention, fasting blood glucose, lipid profile, weight change, BMI and other metabolic indices will be recorded and compared before and after the intervention.
Insulinoma is a rare disease which can cause recurrent hyperinsulinemic hypoglycemia,
subsequent hyperphagia as well as weight gain. As only 50% ~ 60% of pharmacological therapy
(diazoxide, somatostatin, etc) is effective to elevate blood glucose, the nutritional
interventions play a role as an important supportive treatment to maintain glycemic
stablization and control weight gain before the curative surgery. As the essential management
for patients with glycogen storage disease (GSD), the extended release cornstarch has been
proved superior to prevent hypoglycemia since 1980s. Its application has elevated GSD
patients' quality of life and prolonged their survival. In view of its charicteristic of
chronic release in gastrointestinal tract, we will for the first time try to utilize the raw
corn starch (RCS) on patients with suspected insulinoma and evaluate its efficacy of
improving hypoglycemia in such patients.
This will be a prospective single-arm before-and-after clinical trial. Nutritional
intervention with supplementation of RCS will be initiated in 20 patients with suspected
insulinoma to improve their hypoglycemia before the surgery. Duration of nutritional
intervention, fasting blood glucose, lipid profile, weight change, BMI and other metabolic
indices will be recorded and compared before and after the intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
Withdrawn |
NCT02108782 -
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT05034783 -
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
|
Early Phase 1 | |
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
Recruiting |
NCT04185350 -
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
|
Early Phase 1 | |
Recruiting |
NCT00001276 -
Diagnosing and Treating Low Blood Sugar Levels
|
||
Active, not recruiting |
NCT02121366 -
EUS-guided Ethanol Ablation of an Insulinoma
|
N/A | |
Terminated |
NCT00084461 -
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00131911 -
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00005910 -
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
|
N/A | |
Recruiting |
NCT03583528 -
DOTATOC PET/CT for Imaging NET Patients
|
||
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT05523778 -
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
|
N/A | |
Recruiting |
NCT02560376 -
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
|
Phase 0 | |
Completed |
NCT01525082 -
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00655655 -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00075439 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A | |
Active, not recruiting |
NCT01824875 -
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 2 |